logo
Lab-grown salmon is now FDA approved — here's why this one restaurant is putting it on the menu

Lab-grown salmon is now FDA approved — here's why this one restaurant is putting it on the menu

New York Post2 days ago

Land ho! You've heard of fresh-caught salmon and even farm-raised — but what about lab-grown?
San Francisco cellular agriculture company Wildtype is the latest company to get FDA approval for its lab-grown salmon
Only three other companies have gotten the stamp of approval to sell cultivated salmon so far.
The company made waves in the food and culinary sectors after announcing that its hero product, saku salmon, got approved in 'a thorough pre-market safety consultation.'
Curious people can find the fish on the menu at Portland, Oregon, restaurant Kann — a James Beard award-winning Haitian spot by chef Gregory Gourdet.
For June, the cultured salmon will only grace the menu every Thursday night, but in July, it is slated to be a nightly offering.
'Our saku is sushi-grade and best served raw in dishes like sushi, crudo, and ceviche,' Wildtype explains on its website.
'We made it for world-class chefs who seek out the distinct flavor and freshness of raw seafood.'
And according to the FDA, they view lab-grown salmon 'as safe as comparable foods produced by other methods,' the FDA wrote in its public response letter.
The FDA's only gripe with Wildtype's cultivated salmon so far is that the company refers to it as 'cultured salmon cell material' — which is not 'our recommendation of that term as an appropriate common or usual name for declaring the substance in accordance with FDA's labeling requirements,' the agency said.
This interest in lab-grown salmon is due to both wild-caught and farm-raised versions containing levels of mercury. Wild-caught salmon is also susceptible to picking up chemicals in local waters.
So, how exactly is lab-grown salmon made?
The process can be broken down into three steps: source, grow and harvest. Living cells from Pacific salmon are taken from fish and then placed into cell cultivators that mimic the temperature, pH, and nutrients of a wild fish — allowing the cells to grow, as explained by Wildtype.
Once fully matured and harvested, the living 'salmon cells' are fused with plant-based ingredients that imitate the texture and appearance of true salmon.
Experts warn that typically, both wild-caught and farm-raised salmon contain traceable levels of mercury and are susceptible to picking up chemicals in local waters.
Oran Tantapakul – stock.adobe.com
By producing synthetic seafood, Wildtype says it aims to 'sustainably meet the food security challenges of this century' and minimize the damaging environmental implications of farming and fishing practices, while reducing 'exposure to common contaminants we'd rather avoid.'
According to the Washington State Department of Health, farmed salmon can sometimes be exposed to organic contaminants and pests like sea lice more often than wild-caught salmon, but rest assured: 'most of the salmon available for us to eat is farmed,' the agency says.
Synthetic salmon hasn't hit the grocery store shelves just yet but given cultural interest in plant-based, meatless, and lab-grown products — that day seems to be just around the corner.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Transcat to Participate in the Northland Growth Conference 2025
Transcat to Participate in the Northland Growth Conference 2025

Business Wire

time34 minutes ago

  • Business Wire

Transcat to Participate in the Northland Growth Conference 2025

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat, Inc. (Nasdaq: TRNS) ('Transcat' or the 'Company'), a leading provider of accredited calibration services, cost control and optimization services, and distribution and rental of value-added professional grade handheld test, measurement, and control instrumentation, will participate in the Northland Growth Conference 2025 being held virtually on Wednesday, June 25, 2025. Transcat Chief Executive Officer Lee Rudow and Chief Financial Officer Thomas Barbato will conduct one-on-one and small group meetings throughout the conference. Northland Growth Conference 2025 Location: Virtual Format: Virtual 1x1 and Small Group Investor Meetings Attendees: Lee Rudow, Chief Executive Officer, Thomas Barbato, Chief Financial Officer, and Mike West, Chief Operating Officer For more information on the conference, or to schedule a one-on-one meeting with Transcat management, please contact your Northland Capital Markets representative or you may also email your request to TRNS@ or call Chris Tyson at (949) 491-8235. About Transcat Transcat, Inc. is a leading provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing best-in-class services and products to highly regulated industries, particularly the Life Science industry, which includes pharmaceutical, biotechnology, medical device, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. Transcat provides periodic on-site services, mobile calibration services, pickup and delivery, in-house services at its 33 Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Inclusive of customer embedded locations and other field offices, we operate out of more than 50 locations. The breadth and depth of measurement parameters addressed by Transcat's ISO/IEC 17025 scopes of accreditation are believed to be the best in the industry. Transcat also operates as a leading value-added distributor that markets, sells, and rents new and used national and proprietary brand instruments to customers primarily in North America. The Company believes its combined Service and Distribution segment offerings, experience, technical expertise, and integrity creates a unique and compelling value proposition for its customers. Transcat's strategy is to leverage its strong brand and unique value proposition that includes its comprehensive instrument service capabilities, enterprise asset management, and leading distribution platform to drive organic sales growth. The Company will also look to expand its addressable calibration market through acquisitions and capability investments to further realize the inherent leverage of its business model. More information about Transcat can be found at:

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

Yahoo

time39 minutes ago

  • Yahoo

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

Recon Supply Named Exclusive U.S. Distributor of ReShape's STIMEL-03, Lap-Band® 2.0 FLEX, and Full Product Portfolio to Reach U.S. Veterans and Active-Duty Service Members IRVINE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive U.S. distribution agreement with Recon Supply. Through this new strategic partnership, Recon Supply will distribute ReShape's cutting-edge portfolio, including the STIMEL-03 neuromuscular rehabilitation device, the next-generation Lap-Band® 2.0 FLEX, and the full range of ReShape products, across the Veterans Administration (VA) and Department of Defense (DoD) healthcare systems. This collaboration will expand access to proven, life-changing treatments for more than 18 million U.S. veterans and active military personnel. 'This agreement with Recon Supply marks a pivotal step forward in ReShape's mission to expand access to innovative medical technologies that improve lives,' stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. 'Through Recon's extensive footprint across the VA and DoD healthcare systems, we look forward to bringing our FDA-cleared STIMEL-03 system, a cutting-edge neurorehabilitation platform that is transforming clinical care with real-time EMG biofeedback and personalized electrical stimulation, to veterans and military personnel recovering from stroke, injury, or surgery. Additionally, the Lap-Band® 2.0 FLEX, our next-generation, minimally invasive weight loss solution, offers a safe, adjustable option for individuals struggling with obesity. Together, these technologies reflect our commitment to delivering high-impact, clinically proven solutions to patients in need, including those who have served our country.' 'Partnering with ReShape Lifesciences aligns perfectly with our mission to deliver innovative, life-changing medical solutions to those who have served our country,' added Steve Clark, Chief Executive Officer of Recon Supply and a U.S. Marine Corps veteran. 'With established access to VA and DoD facilities through our Distribution and Pricing Agreement (DAPA), Federal Supply Schedule (FSS), and Electronic Catalog (ECAT) contracts, this agreement allows us to expand the reach of ReShape's most impactful technologies—including the STIMEL-03 rehabilitation system and the Lap-Band® 2.0 FLEX. These solutions are well-suited to the complex needs of the veteran and active-duty populations we serve. Since relaunching in 2022, Recon Supply has grown over 113% year-over-year and now distributes to 102 VA Medical Centers nationwide, with a team made up almost entirely of veterans and veteran spouses. We are proud to partner with ReShape to bring these vital solutions to the men and women who have sacrificed for our country.' About Recon SupplyRecon Supply is a trusted distributor of medical products and technologies, specializing in providing high-quality solutions to federal agencies and healthcare systems. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), Recon Supply is dedicated to delivering the most innovative medical technologies while actively supporting the veteran community through hiring initiatives. With a focus on excellence and reliability, Recon Supply is committed to enhancing patient care through innovative partnerships. For more information on Recon Supply, visit About ReShape Lifesciences® ReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational vagal neuromodulation system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit Forward-Looking Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the expectations regarding the distribution arrangement of Recon Supply. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law. CONTACTSReShape Lifesciences Investor Contact:Paul F. HickeyPresident and Chief Executive Officer949-276-7223ir@ Investor Relations Contact:Rx Communications GroupMichael Miller(917)-633-6086mmiller@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering

Yahoo

timean hour ago

  • Yahoo

Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering

- GLIMPSE-1 model achieves state-of-the-art performance in antibody humanization and optimization, enabling scalable, structure-free biologic design from native human immune sequences ALAMEDA, Calif., June 12, 2025--(BUSINESS WIRE)--Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced the launch of GLIMPSE-1, a protein language model trained solely on native human antibody sequences. Developed using millions of paired heavy and light chains from human memory B cells, GLIMPSE-1 represents a new paradigm for therapeutic antibody engineering that applies the design principles of the human adaptive immune system. Infinimmune published results in a new bioRxiv preprint, demonstrating that GLIMPSE-1 can humanize clinical antibodies, engineer for affinity and developability parameters, and generate highly divergent functional variants, all through in silico design guided by the biology of the human adaptive immune system. "Fully human antibodies carry the evolutionary fingerprints of the human immune system, optimized over millions of years," said Wyatt McDonnell, Ph.D., Co-Founder and CEO, Infinimmune. "With GLIMPSE-1, we can decode and encode that logic directly from immune repertoires to discover and design better, safer biologics from day one. This approach complements the FDA's recent focus on assessing human-relevant methods for therapeutic development, which could ultimately benefit patients through more comprehensive safety assessment. We believe models like GLIMPSE-1 will remain essential in the discovery and development of modern antibody medicines." GLIMPSE-1 was developed as a core component of Infinimmune's therapeutic development capabilities, strengthening the company's pipeline of antibody drug candidates. The model was trained using a large, diverse dataset with proprietary sequences from Infinimmune's Complete Human® and Anthrobody® technologies, which source antibodies directly from native human repertoires, allowing it to learn the biological and functional constraints of human immunity. Key results from the preprint include: Best-in-class performance in antibody humanization benchmarks compared to nine leading antibody language models Successful affinity optimization across multiple targets, producing sub-nanomolar variants while addressing developability concerns Creation of highly divergent functional antibody variants with <90% sequence identity to parent sequences Species cross-reactivity engineering across human, cynomolgus monkey, and murine targets Engineering for formulation-preferred parameters such as isoelectric point while maintaining binding affinity GLIMPSE-1 operates entirely in human antibody sequence space, predicting viable antibody variants without 3D structure modeling, energy calculations, or experimental screening beforehand. The resulting antibodies maintain essential functional properties and characteristics consistent with clinically approved monoclonal antibodies, all guided by patterns learned from human immune systems. The development of GLIMPSE-1 aligns with recent FDA initiatives exploring human-relevant methodologies for therapeutic development. The FDA's roadmap for integrating New Approach Methodologies (NAMs) identifies monoclonal antibodies as an initial focus area, creating an environment where human-first models like GLIMPSE-1 may provide valuable complementary insights. Infinimmune has successfully integrated GLIMPSE-1 into its therapeutic antibody development pipeline, where the model has significantly contributed to the engineering and optimization of the company's lead programs. The company is currently exploring strategic partnerships with pharmaceutical and biotechnology companies to apply GLIMPSE-1's capabilities to partner's therapeutic programs. About Infinimmune Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit and follow us on LinkedIn and @infinimmune. View source version on Contacts Media Kimberly HaKKH

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store